Cancer Biomarkers Market Outlook: Advancements in Early Detection and Diagnosis

The global cancer biomarkers market was valued at USD 30.35 billion in 2023 and is projected to reach USD 69.76 billion by 2030, demonstrating a robust Compound Annual Growth Rate (CAGR) of 12.7% from 2024 to 2030. These biomarkers are critical in determining cancer patient prognosis and play a significant role in diagnosing and treating nearly every patient.

The market's growth is primarily fueled by the increasing global incidence of cancer, burgeoning research into cancer biomarkers, their expanding use in drug discovery and development, the rise of individualized treatment approaches, and continuous technological advancements. The escalating global cancer burden, with approximately 20 million new diagnoses and nearly 10 million deaths in 2022 (while 53.5 million people survived for at least 5 years), underscores the urgent demand for early detection and personalized treatment options, solidifying the crucial role of biomarkers in improving cancer diagnosis and therapy. A World Health Organization (WHO) survey highlighted a significant disparity, with less than 40% of countries providing basic cancer care and palliative services, further emphasizing the need for advanced diagnostic and treatment tools like biomarkers.

Moreover, the accelerating research in cancer biomarkers is propelling market expansion by enhancing early detection, diagnosis, and personalized treatment strategies. This growing focus highlights the vital role of biomarkers in improving cancer care outcomes. For instance, the OPTIC RCC clinical trial is investigating personalized treatment for kidney cancer by analyzing a patient's tumor genes to predict the most effective therapy, building on existing knowledge to improve patient outcomes.

Key Market Trends & Insights

• North America dominated the cancer biomarkers market in 2023, holding a 43.84% revenue share. This leadership is attributed to the strong presence of key market players dedicated to cancer biomarkers and substantial investments in research and development by the U.S. government, fostering innovation.

• Within North America, the U.S. cancer biomarkers market was dominant with an 85.8% share in 2023. This growth is largely driven by the availability of new drugs, a robust development pipeline, and the rising incidence of renal cancer, which is linked to the growing geriatric population and increasing smoking habits.

• By type, the breast cancer segment held a significant market share in terms of revenue in 2023 and is anticipated to exhibit the fastest CAGR over the forecast period. Key drivers for breast cancer biomarkers include the high prevalence of the disease, advancements in genomic and proteomic technologies, increased funding for breast cancer research, and a growing emphasis on personalized medicine.

• Based on biomolecule, the genetic biomarkers segment dominated the market in terms of revenue share in 2023. Genetic biomarkers are crucial due to advancements in genomic technologies that enable more precise identification of genetic mutations associated with cancer susceptibility and progression.

• In terms of application, the diagnostics segment held the largest market share in terms of revenue in 2023. This is driven by the increasing development of highly efficient and effective oncology tests based on cancer biomarkers and growing government initiatives in this area.

Order a free sample PDF of the Cancer Biomarkers Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2023 Market Size: USD 30.35 Billion

• 2030 Projected Market Size: USD 69.76 Billion

• CAGR (2024-2030): 12.7%

• North America: Largest market in 2023

• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights

Key companies in the cancer biomarkers market, including Abbott Laboratories, QIAGEN, Thermo Fisher Scientific Inc., Affymetrix Inc., Illumina, Inc., Agilent Technologies, F. Hoffmann-La Roche AG, Merck & Co. Inc., Hologic, Inc., and Sino Biological Inc., are actively working to expand their customer base and gain a competitive advantage. This involves strategic initiatives such as mergers, acquisitions, and partnerships with other major companies.

• Abbott provides a diverse range of assays for various cancer types, including breast and colon, along with personalized oncology testing solutions for early detection, diagnosis, and monitoring.

• QIAGEN offers comprehensive services for sample collection and data interpretation, leveraging advanced technologies and resources to aid in the detection, analysis, and validation of relevant biomarkers, continuously innovating and expanding its solutions.

Key Players

• Abbott

• QIAGEN

• Thermo Fisher Scientific Inc

• Affymetrix Inc

• Illumina, Inc.

• Agilent Technologies

• F. Hoffmann-La Roche AG

• Merck & Co. Inc

• Hologic, Inc

• Sino Biological Inc

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The global cancer biomarkers market is on a significant upward trajectory, driven by the increasing global cancer burden and the escalating demand for early detection, precise diagnosis, and personalized treatment strategies. The continuous advancements in research, particularly in genetic biomarkers and the application of real-time diagnostics, are pivotal to this growth. With substantial investments in R&D and a growing emphasis on individualized medicine, the market is set to play an even more critical role in improving patient outcomes and revolutionizing cancer care worldwide.